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Transplantation in Peripheral T Cell Lymphoma (PTCL):
Analysis of Prognostic Factors
Auayporn Nademanee,1 Joycelynne M. Palmer,2 Leslie Popplewell,1 Ni-Chun Tsai,2
Maria Delioukina,1 Karl Gaal,3 Ji-lian Cai,4 Neil Kogut,4 Stephen J. Forman1Patients with peripheral T cell lymphoma (PTCL) have a poor prognosis with current treatment approaches.
We examined the outcomes of high-dose therapy (HDT) and autologous hematopoietic cell transplant
(AHCT) on the treatment of PTCL and the impact of patient/disease features on long-term outcome.
Sixty-seven patients with PTCL–not otherwise specified (n 5 30), anaplastic large cell lymphoma (n 5
30), and angioimmunoblastic T cell lymphoma (n5 7) underwent HDT/AHCTat the City of Hope. The me-
dian age was 48 years (range: 5-78). Twelve were transplanted in first complete remission (1CR)/partial re-
mission (PR) and 55 with relapsed or induction failure disease (RL/IF). With a median follow-up for surviving
patients of 65.8 months (range: 24.5-216.0) the 5-year overall survival (OS) and progression-free survival
(PFS) were 54% and 40%, respectively. The 5-year PFS was 75% for 1CR/PR compared to 32% for RL/IF pa-
tients (P5.01). When the Prognostic Index for PTCL unspecified (PIT) was applied at the time of transplant,
patients in the PIT 3-4 group had 5-year PFS of only 8%. These results show that HDT/AHCT can improve
long-term disease control in relapsed/refractory PTCL and that HDT/AHCT should ideally be applied either
during 1CR/PR, or as part of upfront treatment. More effective and novel therapies are needed for patients
with high-risk disease (PIT 3-4 factors) and allogeneic HCT should be explored in these patients.
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Peripheral T cell lymphoma (PTCL) is an entity
that was introduced relatively recently through the
REAL [1] and World Health Organization (WHO)
classification [2] systems.Themost common aggressive
forms of PTCL are usually nodal in origin and include
PTCL–not otherwise specified (PTCL-NOS), ana-
plastic large cell lymphoma (ALCL), and angioimmu-
noblastic T cell lymphoma (AITL). When compared
to diffuse large B cell lymphoma (DLBCL), PTCL1Department of Hematology and Hematopoietic Cell
plantation; 2Division of Biostatistics; 3Department of
logy, City of Hope National Medical Center, Duarte,
rnia; and 4City of Hope–Southern California Kaiser
anente, Los Angeles, California.
isclosure: See Acknowledgments on page 1488.
dence and reprint requests: Auayporn Nademanee, MD,
tment of Hematology and Hematopoietic Cell Trans-
tion, 1500 East Duarte Road, Duarte, CA 91010-3000
il: anademanee@coh.org).
ctober 26, 2010; accepted February 13, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.02.008patients have more aggressive disease features at
presentation, for example, advanced clinical stage,
B-symptoms, extranodal disease, elevated lactate dehy-
drogenase (LDH) and high International Prognostic
Index score (IPI) [3,4]. Several retrospective studies
have shown that PTCL patients have poorer
outcomes when treated with anthracycline-containing
regimens; the 5-year overall survival (OS) and failure-
free survival rates are 26% and 20%, respectively [5].
The recent International PTCL and National Killer/
T cell Lymphoma Study showed that, unlike DLBCL,
the majority of patients with PTCL (excluding ALCL
anaplastic lymphoma kinase [ALK]-positive patients)
did not benefit from the use of an anthracycline-
containing regimen [6], making the standard combina-
tion chemotherapy regimen for PTCL undefined.
PTCL remains a heterogeneous group of neo-
plasms with variable prognosis; for example, ALK-
positive ALCL has a more favorable prognosis than
other PTCL [7]. Although, historically, the IPI has
been useful in predicting long-term survival and prog-
nosis for both B and T cell non-Hodgkin lymphoma
(NHL), the value of the index is not well established
in certain PTCL subtypes. More recently a new risk
classification system was developed in PTCL-NOS1481
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Prognostic Index for PTCL (PIT) is based on 4 clinical
variables recorded at the time of diagnosis: age (.60
years), performance status (Eastern Cooperative On-
cology Group [ECOG] $2), LDH (.1  normal
value), and bone marrow involvement (yes). The re-
sults of this analysis defined 4 risk groups based on
the number of adverse factors present and was strongly
supported by clear differences in outcome. Through
the application of the PIT classification, the results
showed that nearly half of the patients with PTCL-
NOS experienced dismal survival rates: a 5-year sur-
vival probability of only 26.8%. The results of this
analysis support the assertion that innovative therapeu-
tic strategies are desperately needed for these patients.
HDT and AHCT, which is considered the stan-
dard treatment for relapsed DLBCL, has also been
shown to be an effective salvage therapy for PTCL in
several retrospective studies [9-11]. Given the
general poor prognosis of patients with PTCL,
HDT/AHCT has also been used as part of upfront
treatment or as consolidation therapy during first
remission in several prospective studies [12-15]. A
disappointing aspect of all these studies was the
proportion of patients unable to proceed to AHCT,
approximately one-third, due primarily to disease pro-
gression, which resulted in a progression-free survival
(PFS) rate of only 30% to 53%. To explore the impact
of HDT/AHCT on PTCL and prognostic signifi-
cance of patient/disease characteristics recorded at
the time of transplant, we analyzed a single-institution
case series of 67 poor-risk, relapsed or primary refrac-
tory PTCL treated with HDT/AHCT.PATIENTS AND METHODS
From February 1991 to July 2007, a consecutive
case series of 67 PTCL patients underwent HDT/
AHCT at the City of Hope National Medical Center
(COH). Patients were identified and selected for anal-
ysis from a prospective observational research trans-
plant database. The COH institutional review board
approved the analysis of these data. All pathology spec-
imens were reviewed by the COH Hematopathology
Department to confirm diagnosis prior to transplanta-
tion. The histologic diagnoses were based on WHO
classification. The categories of PTCL-NOS, AITL,
and ALCLwere included in this report. NK/T cell na-
sal/nasal type lymphomas were not included, because
they belong to the extranodal lymphomas according
to the WHO classification. The other rare subtypes
of PTCL were also excluded. Disease status was con-
firmed by clinical assessment including physical exam-
ination, laboratory evaluation, imaging by computed
tomography (CT) scans and nuclear imaging, bone
marrow biopsies, and photo documentation per
COH patient care standard operating procedures.Eligibility Criteria
Patients were eligible for AHCT if they failed to
achieve remission after initial induction chemotherapy
or relapsed postinduction chemotherapy. Patients with
PTCL-NOS, ALK-negative ALCL, and AITL who
had advanced stage, or high-intermediate/high-risk
IPI were eligible for AHCT during first complete
response/partial remission (CR/PR). Patients with
ALK-positive ALCL were transplanted at the time of
relapse or disease progression. All relapsed patients
must have a biopsy to confirm recurrent disease. Pa-
tients were required to have: no bone marrow involve-
ment and normal cytogenetic studies before stem cell
mobilization or bone marrow harvest; and adequate
cardiac, pulmonary, renal, and hepatic functions. Pa-
tients with positive human immunodeficiency virus an-
tibodies were excluded.High-Dose Regimens
Three high-dose regimens were used. Patients
\60 years received total body irradiation (TBI) 1200
cGy (days 28 to 25) followed by etoposide (VP16)
60 mg/kg on day 24 and cyclophosphamide (CY)
100 mg/kg on day22. For patients$60 years or those
with prior radiotherapy, carmustine 450 mg/m2 was
given over 3 days on day 27 to day 25 instead of
TBI or high-dose BEAM regimen (carmustine, etopo-
side, cytarabine, and melphalan). No positive selection
or in vitro purging of bone marrow/peripheral blood
stem cells was performed.Response Criteria
CR was defined as the complete resolution of all
measurable disease, sustained for at least 4 weeks. PR
was defined as a 50% or more reduction in the sum
of the products of the diameters of all measurable le-
sions. Induction failure (IF) was defined as failure to
achieve at least a PR with anthracycline-containing
first-line therapy, or progression from a CR or PR
within 4 weeks of first-line treatment. Relapse was de-
fined as a clinical or radiologic progression at least 4
weeks after an initial CR or PR to first-line therapy.
Salvage chemotherapy was given to debulk disease
and to determine chemosensitivity before AHCT.
Chemosensitivity was defined as at least a PR to sal-
vage treatment and resolution of all disease-related
symptoms, maintained for at least 4 weeks.
Staging was performed at relapse, after salvage
chemotherapy before AHCT, 100 days, 6 months,
12 months, every 6 months until 2 years posttrans-
plant, and then every year thereafter or as clinically in-
dicated. Staging included physical examination,
complete blood counts, biochemical profiles, LDH,
chest X-ray, computed topographies of the chest, ab-
domen, and pelvis, and unilateral or bilateral bone
Biol Blood Marrow Transplant 17:1481-1489, 2011 1483AHCT in PTCLmarrow biopsy if indicated. The IPI was calculated
according to standard variables [16]. The PIT was
calculated for each patient at the time of AHCT based
on age, LDH level, performance status, and bone mar-
row involvement.Statistical Analysis
Survival estimates were calculated based on the
Kaplan-Meier product-limit method; 95% confidence
intervals were calculated using the logit transforma-
tion and the Greenwood variance estimate [17]. Dif-
ferences between Kaplan-Meier curves were assessed
by the log-rank test. Patients who were alive at the
time of analysis were censored at the last contact
date. OS was measured from transplant to death
from any cause. PFS was defined as time from trans-
plant to recurrence, progression, or death. Event-free
survival (EFS) was defined as time from transplant to
progression, secondary malignancy, or death. The
relapse/progression rate (RPR) was defined as time
from transplant to recurrence or progression. The cu-
mulative incidence for RPR was computed treating
a nonrelapse death event as a competing risk. Nonre-
lapse mortality (NRM) was measured from transplant
to death from any cause other than disease relapse or
disease progression. Nonrelapse-related mortality
and relapse-relatedmortality were considered compet-
ing risks for mortality. The cumulative incidence of
NRM and relapse-related mortality was calculated us-
ing the method described by Gooley et al. [18]. Differ-
ences between cumulative incidence curves in the
presence of a competing risk were tested using the
Gray method [19]. The significance of demographic
and treatment features was assessed using survival
analysis and univariate Cox proportional hazards
regression analysis [20].
Univariate Cox proportional hazard models
were used to model time to event endpoints (eg, OS,
PFS, EFS, RPR, and NRM) as a function of the prog-
nostic variables. The list of prognostic variables was
determined from a literature review that identified fac-
tors associated with survival and/or disease relapse/
recurrence in patients treated with AHCT. These
variables were: histopathologic subtype, patient age
at AHCT (\60 years, $60 years), disease status at
the time of AHCT (1CR/PR; 2CR/RL; IF), disease
stage at AHCT, Karnofsky Performance Status
(KPS) at AHCT ($90, \90), LDH (normal, high),
bone marrow involvement at AHCT (yes, no), prior
radiation treatment (yes, no), number of prior regi-
mens (.1, #1), and chemosensitive disease (yes, no).
All calculations were performed using SAS 9.2 (SAS
Institute, Cary, NC). Statistical significance was
set at the P\ .05 level; all P values were two sided.
The data were locked for analysis onMay 22, 2009 (an-
alytic date).RESULTS
Patient Characteristics
Between February 1991 and July 2007, 67 consec-
utively treated patients with PTCL underwent HDT/
AHCT (Table 1). The median age was 48 years
(range: 5-78), and 42 (63%) were male. The median
time from diagnosis to transplant was 11.6 months
(range: 3.7-123.0). The histology subtypes included
ALCL, n 5 30; PTCL-NOS, n 5 30; and AITL
n 5 7. Among the 30 patients with ALCL, 13 were
ALK-negative, 11 were ALK-positive, and 6 were
not tested. Fifty-three (79%) had advanced stage (III
or IV) at diagnosis. Twelve (18%) received transplants
in first CR or first PR, 21 were in second CR, 14 were
in relapse, and 20 failed induction chemotherapy. All
patients received CHOP (cyclophosphamide, adria-
mycin, oncovin, and prednisone) (57 patients) or
CHOP-like regimen (10 patients) as induction che-
motherapy. Intensive regimens were not used in first
remission patients. The salvage regimens commonly
used were ICE (ifosamide, carboplation, etoposide),
ESHAP (etoposide, steroid, cytarabine, cisplatin), or
gemcitabine-based regimens. Eighteen patients re-
ceived .2 salvage regimens.
At transplantation, 24 patients (36%) had stage III
or IV disease and 55 (82%) were PIT group 1-2,
whereas 12 were PIT group 3-4. The median number
of prior regimens was 2 (range: 1-5). Most patients re-
ceived peripheral blood stem cells, and 41 (61%) re-
ceived a TBI-based conditioning regimen.Treatment Outcome
At a median follow-up of 33.6 months (range: 0.5-
216) for all patients and 65.8 months (range: 24.5-216)
for surviving patients, 37 patients (55%) were alive and
30 (45%) expired (Table 2). The 5-year OS and PFS
was 54% (95% confidence interval [CI]: 47%-60%)
and 40% (95% CI: 35%-44%), respectively
(Figure 1a). The 5-year EFS estimate was similar to
PFS, although slightly lower: 35% (95% CI: 31-39)
(Figure 1b). The 5-year PFS was significantly better
for patients who were transplanted during 1CR/PR
compared to those transplanted beyond 1CR/PR
(75% versus 32%, P5 .0138) (Figure 2). The same ad-
vantage was seen among 1CR/PR patients for OS at 5
year: 92% versus 45%, P5 .0115) and EFS at 5 years:
75% versus 26%, P5 .0062). The RPRwas also signif-
icantly higher for those transplanted beyond 1CR/PR;
the 2-year RPRwas 60% versus 25%, P5 .038. The 5-
year PFS probability was significantly worse for PIT
group 3-4 when compared to PIT group 1-2 (8% ver-
sus 47%, P 5 .0004) (Figure 3); the same was true for
EFS at 5 years (8% versus 40%, P 5 .0007). There
were no statistically significant differences in outcome
across the 3 histologic subtypes. For the subset of
Table 1. Patient, Disease, and Transplant Characteristics
N (%) or
Median (Range)
Patient Gender
Female 25 (37)
Male 42 (63)
Age at transplant (years) 48 (5-78)
Time from diagnosis to transplant (months) 11.6 (3.7-123.4)
Histology
AITL 7 (10)
ALCL 30 (45)
PTCL-NOS 30 (45)
ALCL
ALK positive 11 (37)
ALK negative 13 (43)
Not tested 6 (20)
Disease status at transplant
First complete remission 11 (16)
First partial remission 1 (2)
Second complete remission 21 (31)
First relapse 12 (18)
Second relapse 2 (3)
Induction failure 20 (30)
Stem cell source
Bone marrow 4 (6)
Peripheral blood 63 (94)
Conditioning regimen
TBI/VP16/CY 41 (61)
BCNU/VP16/CY 19 (29)
BEAM 7 (10)
Chemosensitivity
Sensitive 56 (84)
Resistant 11 (16)
Stage at diagnosis
I 6 (9)
II 8 (12)
III 21 (31)
IV 32 (48)
KPS at diagnosis 90 (40-100)
Stage at transplant
I 6 (9)
II 2 (3)
III 11 (17)
IV 13 (19)
Not applicable 35 (52)
KPS at transplant 90 (60-100)
Number of prior regimens 2 (1-5)
PIT group
1-2 55 (82)
3-4 12 (18)
AITL indicates angioimmunoblastic T cell lymphoma; ALCL, anaplastic
large cell lymphoma; PTCL-NOS, peripheral T cell lymphoma–not
otherwise specified; ALK, anaplastic lymphoma kinase; TBI, fractioned
total body irradiation; VP16, etoposide; CY, cyclophosphamide;
BCNU, carmustine; BEAM, carmustine, etroposide, cytarabine, andmel-
phalan; KPS, Karnofsky performance status; PIT, Prognostic Index for
PTCL unspecified.
Table 2. Summary of Transplant Outcomes
N (%) or
Median (Range)
Engraftment: ANC $500 cells/mL
(Days from transplant to ANC recovery)
10 (8-22)
Engraftment: platelets $20 K cells/mL
(Days from transplant to platelet recovery)
15 (9-778)
Relapse/disease progression posttransplant
Yes 34 (51)
No 33 (49)
Vital status
Alive 37 (55)
Expired 30 (45)
Cause of death
Disease progression/relapse 22
Cardiac/myocardial infarction 3
Interstitial pneumonitis, persistent disease 1
Diffuse pulmonary failure 1
Acute respiratory distress syndrome 1
Information not available 2
Nonrelapse mortality
Yes 8 (12)
No 59 (88)
Mortality at day 100
Expired 3 (5)
Disease progression/relapse 3
Other 0
Alive 64 (95)
Follow-up (months)
All patients 33.6 (0.5-216.1)
Alive 65.8 (24.5-216.1)
Expired 7.7 (0.5-40.5)
Time from transplant to relapse (months) 3.6 (0.7-24.0)
Alive patients, current disease status
CR 27 (73)
Not in CR 10 (27)
ANC indicates absolute neutrophil count; CR, complete remission.
1484 Biol Blood Marrow Transplant 17:1481-1489, 2011A. Nademanee et al.ALCL, there was a trend for better survival in ALK-
positive ALCL compared to ALK-negative ALCL
(5-year OS: 82% versus 54%; 5-year PFS: 73% versus
46%; 5-year EFS: 73% versus 46%); however, the re-
sult did not show significance because of the small
number of patients in each group.Relapse
Thirty-four patients (51%) relapsed at a median
of 3.6 months (range: 0.7-24) post-AHCT. The2-year cumulative incidence of relapse/progression
was 53% (95% CI: 47.8-59.3). There were no
relapse/progression events seen beyond the 2-year
mark, with a plateau achieved and sustained 2 years
posttransplant; a similar finding was also noted for
the survival endpoints. Additionally, there were no
statistical differences seen in relapse/progression risk
among the various histologic subtypes.
Transplant-Related Mortality
Transplant-related mortality at day 100 was 0.0%,
and NRM was 6.3% at 1 year. There were 8 deaths
during the first year posttransplant because of cardiac
causes (n5 3), pulmonary complication/acute respira-
tory distress syndrome (n5 3), and unknown causes (n
5 2). One patient developed therapy-induced myelo-
dysplasia at 4 years post-AHCT and was successfully
treated with allogeneic stem cell transplant. Another
patient developed therapy-induced acute myelogenous
leukemia at 18 months post-AHCT and died from car-
diac causes.
Univariate andMultivariate Analysis: Prognostic
Factors
The univariate analysis results for PFS and RPR
are summarized in Table 3. The factors studied
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Figure 1. (A) Probabilities of OS and PFS. (B) Probabilities of OS and EFS.
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age, stage at transplant, bone marrow involvement at
AHCT, extranodal involvement at AHCT, chemosen-
sitivity, conditioning, PIT at AHCT, KPS at AHCT,
and number of prior chemotherapy regimens. Disease
status at AHCT, stage, age, KPS, LDH, and PIT
group were found to be significant predictors univari-
ately for PFS. The same was true for EFS. Similar fac-
tors, with the exception of age, were found to be
significant predictors for RPR. An increase in hazard
was seen among high-risk groups across all significant
factors. The multivariate model, which included
variables found to be significant univariately at the
P # .10 level, showed that after adjusting for all other
factors the single most significant factor was the
AHCT PIT group. This was true for both endpoints:
PFS and RPR. Themodeling results for EFSwere very
similar to PFS.DISCUSSION
Our results represent the largest single center ex-
perience of HDT/AHCT for PTCL and confirms
that HDT/AHCT is an effective salvage therapy for
patients with relapsed or refractory PTCL and about
a third of patients can achieve long-term disease con-
trol with this treatment. Because we observed a plateau
in survival and there were no relapses/progression
events 2 years posttransplant, these data suggest that
HDT/AHCT may be a curative treatment for this ag-
gressive disease.
In contrast to other reports, there were no differ-
ences in survival seen between ALCL and other
PTCL subtypes in our study; we believe this may be
because of small numbers. The impact of histologic
subtype on HDT/AHCT outcomes have been evalu-
ated in several studies and showed a superior outcome
Figure 2. PFS stratified by disease status at transplant.
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Jagasia et al. [21] reports a 3-year OS of 86% for ALCL
compared to 47% for non-ALCL histology (P 5
.0122).However, analysis based on ALK status showed
that ALK-positive ALCL patients had a superior EFS
compared to ALK-negative ALCL (100% versus 0%;
P5 .0228). Different results were reported from a ret-
rospective study of T cell lymphoma patients treated
with HDT/AHCT from the GEL-TAMO Group. In
this study, ALCLhistology did not prove to have a pos-
itive impact on outcome [22]. Because patient selection
and ALK status might account for these differences in
outcome, ALK status should be included in future
studies. In our study, we found a trend toward im-
proved survival in ALK-positive ALCL. Although
the analysis of prognostic factors post-HDT/AHCT
are often hampered by the small number of patients
and heterogeneity of the patient population, mostS
u
r
v
i
v
a
l
 P
r
o
b
a
b
il
it
y
0.0
0.2
0.4
0.6
0.8
1.0
Time (Years) f
0 2 4 6 8 1
Figure 3. PFS stratifiestudies have shown that chemosensitivity and response
to salvage chemotherapy are predictive of better sur-
vival. TheM.D. Anderson [23] and the Spanish Group
for Lymphoma and AHCT (GEL-TAMO) [24] both
identified pretransplant LDH and IPI as the most im-
portant predictors for survival. More recently, PIT has
been used to predict outcome of HDT/AHCT in
PTCL. Yang et al. [25] analyzed factors post-HDT/
AHCT in 64 Korean patients with PTCL-NOS.
They found that failure to achieve CR at transplant
and PIT 2-3 were associated with decreased survival
posttransplant. The 3-year OS was only 7.5% for
PIT 2-3 groups. In another study reported by the
Spanish Lymphoma and Autologous Transplantation
Group, PIT was also found to predict outcome in 74
patients with PTCL who were transplanted in first
CR [22]. Patients with PIT 3-4 had 5-year OS and
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Table 3. Univariate/Multivariate Cox Regression Analysis
Progression-Free Survival Relapse/Progression Rate
Univariate Multivariate Univariate Multivariate
Variable Value N
No.
of Events
Hazard
Rate Ratio
(95% CI) P- Value
Hazard
Rate Ratio
(95% CI) P Value
No.
of Events
Hazard
Rate Ratio
(95% CI) P Value
Hazard
Rate Ratio
(95% CI) P Value
Histology at transplant 0: AILD/ALCL 37 19 Baseline .166 Baseline * 16 Baseline .193 Baseline *
1: PTCL 30 21 1.56 (0.83, 2.91) N/A 18 1.57 (0.8, 3.09) N/A
Disease status
at transplant
0: 1CR/PR 12 3 Baseline .023 Baseline .030 3 Baseline .050 Baseline .123
1: 2CR/RL/IF 55 37 3.94 (1.21, 12.82) 3.92 (1.14, 13.48) 31 3.28 (1.00, 10.75) 2.72 (0.76, 9.69)
Stage at transplant 0: N/A 35 17 Baseline .024 Baseline .587 12 Baseline .004 Baseline .153
1: I-IV 32 23 2.07 (1.1, 3.88) 1.21 (0.61, 2.40) 22 2.81 (1.38, 5.69) 0.77 (0.81, 3.85)
Age at transplant 0: <60 51 27 Baseline .036 Baseline * 24 Baseline .151 Baseline *
1: $60 16 13 2.05 (1.05, 4) N/A 10 1.72 (0.82, 3.61) N/A
KPS at transplant 0: 90-100 56 31 Baseline .032 Baseline * 26 Baseline .030 Baseline *
1: #80 11 9 2.28 (1.07, 4.82) N/A 8 2.43 (1.09, 5.41) N/A
LDH at transplant 0: Normal 40 17 Baseline .002 Baseline * 14 Baseline .003 Baseline *
1: Elevated 26 22 2.72 (1.43, 5.16) N/A 19 2.84 (1.41, 5.71) N/A
Number of prior
regimens
0: #2 12 27 Baseline .387 Baseline * 23 Baseline .444 Baseline *
1: >2 55 13 1.34 (0.69, 2.60) 2.51 (0.7, 9.04) 11 1.32 (0.65, 2.72) N/A
Chemosensitivity 0: SR 56 33 Baseline .600 Baseline * 28 Baseline .582 Baseline *
1: RR 11 7 1.24 (0.55, 2.82) N/A 6 1.28 (0.53, 3.1) N/A
PIT group 0: Level 1/2 55 29 Baseline .001 Baseline .001 24 Baseline .001 Baseline .002
1: Level 3/4 12 11 3.38 (1.66, 6.89) 3.49 (1.65, 7.39) 10 3.78 (1.78, 8.05) 3.52 (1.59, 7.79)
KPS indicates Karnofsky Performance Status; PIT, Prognostic Index for PTCL unspecified; LDH, lactate dehydrogenase; CI, confidence interval; CR, complete response; PR, partial remission.
*Not entered into multivariate model.
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confirms the prognostic value of PIT using patient
values recorded pretransplant. Furthermore, our data
suggest that PIT may be used to identify patients
who likely will not benefit from AHCT, making alter-
native treatment approaches such as clinical trials or al-
logeneic HCT a more plausible option.
Although our results do support the role of HDT/
AHCT during first CR/PR in PTCL, the role of
AHCT for aggressive lymphoma patients in first CR
is still an unresolved issue. There is evidence that
HDT/ASCT may improve the outcome of selected
first CR patients, mainly those with a high IPI score
[26]. There are 5 prospective studies of HDT
and AHCT during first CR/PR in PTCL
[12,13,15,14,27]. Reimer et al. [15] reported results
of a multicenter study of upfront AHCT in PTCL.
Eighty-three patients were treated with 4 to 6 cycles
of CHOP followed by AHCT. Sixty-six percent were
able to proceed to AHCT. The estimated 3-year OS,
DFS, and PFS were 48%, 53%, and 36%, respectively.
More intensive induction chemotherapy such as
CHOEP-14 (CHOP plus etoposide) [27] or Mega-
CHOP/ESHAP [13] were used in other studies; how-
ever, about 23% to 59% of the patients were still
unable to undergo AHCT mainly because of disease
progression and about 25% of those who did undergo
AHCT during first CR experienced relapse posttrans-
plant. Nevertheless, HDT/AHCT as consolidation
therapy during first CR is probably the most effective
approach to improve prognosis of PTCL patients and
should be further investigated in prospective random-
ized trials.
To explore whether the graft-versus-lymphoma
effect exists in PTCL, allo-HCT has been performed
in patients with refractory PTCL. Encouraging results
were reported by Corradini et al. [28] in 17 patients
with relapsed/refractory PTCL following reduced-
intensity allo-HCT. The estimated 3-year OS and
PFS were 81% and 64%, respectively, with a 2-year
NRM of only 6%. Recently, Le Gouill et al. [29] re-
ported their retrospective experiences of allo-HCT
in 77 patients with several subtypes of T cell NHL
from the Societe Franc¸aise de Greffe de Moelle et de
Therapie Cellulaire (SFGM-TC). The median age
was 36 years, and 74% received a myeloablative regi-
men. The 5-year OS and EFS were 57% and 53%, re-
spectively; however, the 5-year TRM was high at 34%
probably related to the use of a myeloablative regimen.
Even though allo-HCTmay be an effective therapy for
PTCL, further studies to define the optimal condi-
tioning regimens and the group of patients who would
benefit most from allo-HCT are necessary. Similarly,
the role of reduced-intensity allo-HCT in PTCL
needs further investigation.
We conclude from our analysis, that one-third of
patients with relapsed or refractory PTCLmay achievelong-term disease control with HDT/AHCT, a treat-
ment that is associated with low acute transplant-
related toxicity. Unfortunately, this approach does
not seem to overcome the disease in patients with the
poorest prognosis because relapse/progression events
continue to occur. New innovative therapies are
needed to induce remission in patients with PTCL so
more patients with relapsed or refractory disease can
be eligible for HDT/AHCT. Encouraging results
have been reported with newer agents such as antime-
tabolite pralatrexate or histone deacetylase inhibitors
in PTCL, and incorporation of these agents into the
treatment plan are being investigated. Our results
based on small number of patients show that patients
with high PIT scores do poorly with HDT/AHCT,
and perhaps should be offered clinical trials or evalu-
ated for allo-HCT. Given the poor outcome with con-
ventional chemotherapy and AHCT at relapse in
PTCL patients, HDT/AHCT during first remission
should be recommended and further investigated in
prospective randomized clinical trials. Additional stud-
ies are needed to evaluate the role of reduced intensity
allo-HCT in PTCL patients.ACKNOWLEDGMENTS
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